ly3561774
Nucleic acidexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2020 (NCT04644809)
Timeline
Indications
Mechanism of action
- Angiopoietin-related protein 3INHIBITOR
ANGPTL3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314638 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07269210 | Phase 2 | Dec 31, 2025 | Eli Lilly |
| NCT05256654 | Phase 2 | Jul 20, 2022 | Eli Lilly |
| NCT04644809 | Phase 1 | Nov 30, 2020 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 2 | 2020 |
1 organizations
Page 1 / 1